galectin-14 Inhibitors
Galectin-14 Inhibitors consist of various compounds that can inhibit the functional activity of galectin-14 by targeting its carbohydrate recognition domain (CRD) or interfering with the glycosylation patterns of its ligands. These compounds include simple sugars like lactose and galactose, which can compete with endogenous ligands for binding to the CRD, thereby inhibiting galectin-14's ability to mediate cell-cell or cell-matrix interactions and signal transduction. Additionally, glycosidase inhibitors such as castanospermine and deoxygalactonojirimycin can alter the glycosylation patterns of proteins, potentially reducing the interaction of galectin-14 with its ligands. Such altered glycosylation could inhibit the functional activity of galectin-14 by interfering with its ability to engage in physiological processes.
Further, compounds like benzyl-2-acetamido-2-deoxy-α-D-galactopyranoside and thiodigalactoside mimic the structure of galectin-14 ligands and can act as competitive inhibitors by occupying the CRD, preventing the interaction with physiological ligands.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lactose | 63-42-3 | sc-221828A sc-221828 sc-221828B | 500 g 1 kg 2.5 kg | $109.00 $160.00 $352.00 | 1 | |
A disaccharide that can bind to the carbohydrate recognition domain (CRD) of galectins, potentially inhibiting galectin-14's ability to bind to its endogenous ligands on cell surfaces or extracellular glycoconjugates, therefore inhibiting its functional activity. | ||||||
D-Galactose | 59-23-4 | sc-202564 | 100 g | $288.00 | 4 | |
A monosaccharide that competes with endogenous ligands for the CRD of galectin-14, which could inhibit the protein's ability to mediate cell-cell or cell-matrix interactions and signal transduction. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
An indolizidine alkaloid that inhibits glycosidase enzymes, potentially altering glycoprotein processing and thus the availability of functional ligands for galectin-14, leading to its functional inhibition. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
An indolizidine alkaloid that inhibits mannosidase, could prevent the proper glycosylation of glycoproteins, potentially decreasing the availability of functional ligands for galectin-14 binding. | ||||||
Benzyl-2-acetamido-2-deoxy-α-D-galactopyranoside | 3554-93-6 | sc-203427 sc-203427A | 100 mg 1 g | $350.00 $3184.00 | 2 | |
A synthetic molecule that mimics the structure of N-acetylgalactosamine, could competitively inhibit galectin-14 by occupying its CRD and preventing interaction with physiological ligands. | ||||||
Pectin from citrus peel | 9000-69-5 | sc-255409 sc-255409A | 100 g 500 g | $65.00 $194.00 | 1 | |
A complex polysaccharide containing galactoside chains that can bind to galectins, potentially inhibiting galectin-14 by preventing its interaction with cellular glycoconjugates. | ||||||
Fucoidan | 9072-19-9 | sc-255187 sc-255187A | 5 g 10 g | $190.00 $318.00 | 7 | |
A sulfated polysaccharide that can bind to a variety of proteins, including galectins. It could inhibit galectin-14 by blocking its CRD and interfering with its cellular functions. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
A monosaccharide that can compete with galactose-binding sites on galectins, potentially inhibiting galectin-14's glycoconjugate binding and subsequent cellular functions. | ||||||